Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Precipio Inc (PRPO) USD0.01

Sell:$2.92 Buy:$2.95 Change: $0.1 (3.26%)
Market closed |  Prices as at close on 16 September 2021 | Switch to live prices |
Change: $0.1 (3.26%)
Market closed |  Prices as at close on 16 September 2021 | Switch to live prices |
Change: $0.1 (3.26%)
Market closed |  Prices as at close on 16 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Precipio, Inc. is a cancer diagnostics and reagent technology company providing diagnostic products and services to the oncology market. The Company is focused on developing various technologies including IV-Cell, HemeScreen and ICE-COLD-PCR (ICP). The IV-Cell is a cell culture media that addresses the problem of selective and serial culturing. IV-Cell is a media that enables culturing of all four hematopoietic cell lineages, which include myeloid cells, B-cells, T-cells and plasma cells. The diagnostic process of hematopoietic diseases involves chromosomal analysis by conducting cell-culture based tests by a cytogenetics laboratory to imitate in-vivo conditions. HemeScreen technology was developed by the Company targeting Myeloproliferative Neoplasms (MPN), which has evolved into a suite of robust genetic diagnostic panels. ICP technology was developed at Harvard and is licensed exclusively by Dana-Farber. The Company operate a cancer diagnostic laboratory located in New Haven.

Contact details

12325 Emmet St
United States
+1 (203) 7877888

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$67.90 million
Shares in issue:
22.71 million
Health Care Services
United States
US dollar

Key personnel

  • Ilan Danieli
    Chief Executive Officer, Director
  • Carl Iberger
    Chief Financial Officer
  • Ahmed Sabet
    Chief Operating Officer
  • Ayma Mohamed
    Vice President - Research and Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.